Omics of Rituximab-resistance
ConditionMembranous Nephropathy
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorMario Negri Institute for Pharmacological Research
About this trial
The CONFUCIUS project aims to establish a personalised medicine framework for MN patients by integrating pharmacogenomics with other -omics technologies in order to identify biomarkers that predict response to RTX, ultimately enabling optimized treatment selection. Using a multiomics approach, we will analyse genetic variants, serum and kidney proteomics, and serum metabolomics profiles from a well-characterised retrospective cohort of MN patients to uncover predictive biomarkers of RTX response.
This is a non-pharmacological interventional study, conducted on biological samples from patients stored in the local biobank and on samples from healthy volunteers, which will be collected and subsequently stored in the biobank.
Eligibility criteria
Qualifiers
Adult patients
Biopsy-proven primary membranous nephropathy (MN)
Written informed consent for storage of biological samples in the local biobank
Disqualifiers
Absence of signed written informed consent for the storage of samples in the biobank
Adult male and female
Written informed consent
History of renal diseases, autoimmune disorders, diabetes mellitus, current allergies
Trial design
Treatments tested in this trial
- Multi-omics Analysis
- Sample collection
Treatment groups
120 Participants
are divided into 3 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov